Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Private Placement

27 Sep 2011 13:30

RNS Number : 0201P
Emerging Metals Limited
27 September 2011
 



For Immediate Release: 27 September 2011

 

Emerging Metals Limited

("EML" or the "Company")

 

Private Placement

Dealings by Directors

 

Further to the announcement made on 15 September 2011, EML is pleased to announce that the Company has completed, subject only to Admission, a private placement to parties (including certain EML directors) raising gross proceeds of £2,000,000 through the issue of 100,000,000 new ordinary shares at a price of 2p per share (the "Placing").

 

The majority of the proceeds will be advanced to the Company's 37.23 per cent associated company Ferrum Resources Limited to fund its on-going exploration programme in Sierra Leone. By loan agreement dated 27 September 2011 the Company has advanced £1,000,000 to Ferrum. The loan is secured against assets of Ferrum and is (unless agreed otherwise in writing by the parties) repayable together with interest (charged at a rate of 10 per cent. per annum) on 23 March 2012.

 

Certain EML directors have participated in the Placing as set out in the table below:-

 

Name

Number of new shares

Resultant holding of Ordinary Shares

Percentage of enlarged share capital

Stephen Dattels*

17,000,000

38,820,313

8.44%

James Mellon**

20,000,000

51,333,493

11.15%

 

* - These shares are held by Regent Mercantile Holdings Limited, a company itself owned by trustees of a trust under which Stephen Dattels and members of his family may become beneficiaries and are registered in the name of Goldman Sachs Securities (Nominees) Limited.

** - The new shares are being subscribed by Galloway Limited ("Galloway"), bringing its total holding to 47,915,141 shares, representing 10.41% of EML's enlarged issued share capital. Galloway, whose directors include Denham Eke, is indirectly wholly owned by the trustee of a settlement under which James Mellon has a life interest. The balance of James Mellon's shareholding is held in his own name.

 

EML's independent directors (excluding for these purposes Messrs. Eke, Dattels and Mellon), consider the terms of the Placing to be fair and reasonable insofar as EML's shareholders are concerned, having consulted with the Company's nominated adviser.

 

Following the Placing, the Company is aware of the following persons who hold, directly or indirectly, voting rights representing 3% or more of the enlarged issued share capital of the Company to which voting rights are attached:

 

Name

Number of Ordinary Shares

Percentage of enlarged share capital

Vidacos Nominees Limited

129,820,500

28.21%

James Mellon**

51,333,493

11.15%

Stephen Dattels*

38,820,313

8.44%

Mr Ronald Bruce Rowan

25,000,000

5.43%

Middlemarch Partners Limited

22,000,000

4.78%

 

Application will be made for the new ordinary shares, which rank pari passu in all respects with the Company's existing ordinary shares, to be admitted to trading on AIM which is expected to occur no later than Monday 3 October 2011. Following the issue, the Company's total issued ordinary share capital will be 460,187,559 Ordinary Shares.

 

For further information:

 

Emerging Metals Limited

Religare Capital Markets Limited

Evolution Securities Limited

GTH Communications

Denham Eke

Peter Trevelyan-Clark

Emily Staples

 

Romil Patel

Tim Redfern

Toby Hall

Christian Pickel

+44 (0) 1624 639396

+44 (0) 20 7444 0800

+44 (0)20 7071 4300

+44 (0) 20 3103 3902

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBDGDCIDDBGBR
Date   Source Headline
19th May 20238:00 amRNSADS Program collapse
15th May 20237:00 amRNSChange of Record Time and Last Day of Dealings
11th May 202312:00 pmRNSWebull Corporate Communications Service Platform
11th May 20237:00 amRNSChange of Delisting Date to 22 May 2023
3rd May 20231:00 pmRNSResult of Meeting
3rd May 20237:00 amRNSPresentation on OK-101 at ASCRS
2nd May 20237:00 amRNSFirst-Patient First-Visit for Phase 2 Trial
25th Apr 20237:00 amRNSActivation of First Clinical Trial Site in the U.S
5th Apr 20237:00 amRNSNOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATION
4th Apr 20237:00 amRNSNotice Of Intention To Delist From The LSE
30th Mar 20237:00 amRNSDirector Acquires Shares
29th Mar 20237:00 amRNSDirector acquires shares
24th Mar 20237:00 amRNSDirector/PDMR Shareholding
16th Mar 20237:01 amRNSListing of Trial on the ClinicalTrials.gov Website
16th Mar 20237:00 amRNSClosing of Global Private Placement
15th Mar 20237:01 amRNSDirector/PDMR Dealings
14th Mar 20237:00 amRNSIssue of Equity
13th Mar 20233:16 pmRNSCEO Interview
6th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSCustom Clearance of GMP Packaged OK-101 Drug
23rd Feb 20237:00 amRNSAppointment to Scientific Advisory Board
21st Feb 20237:00 amRNSCorporate Presentation
20th Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20232:05 pmRNSSecond Price Monitoring Extn
20th Feb 20232:00 pmRNSPrice Monitoring Extension
20th Feb 202311:05 amRNSSecond Price Monitoring Extn
20th Feb 202311:00 amRNSPrice Monitoring Extension
20th Feb 20239:05 amRNSSecond Price Monitoring Extn
20th Feb 20239:00 amRNSPrice Monitoring Extension
17th Feb 20234:40 pmRNSSecond Price Monitoring Extn
17th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20237:00 amRNSAllotment of Shares and Total Voting Rights
10th Jan 20234:40 pmRNSSecond Price Monitoring Extn
10th Jan 20234:35 pmRNSPrice Monitoring Extension
10th Jan 20232:05 pmRNSSecond Price Monitoring Extn
10th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 20231:15 pmRNSInterim Results - availability
30th Dec 20227:00 amRNSInterim Results for the Six Months Ending 30Sept22
22nd Dec 20227:00 amRNSU.S. FDA Clearance of IND Application for OK-101
21st Dec 20227:00 amRNSOKYO to Participate at Biotech Showcase
6th Dec 20227:00 amRNSOKYO files a registration statement with the SEC
1st Dec 20227:00 amRNSChange of Auditor
24th Nov 20227:00 amRNSDirector/PDMR Shareholding
21st Nov 20227:00 amRNSU.S. IND Filing on OK-101 for the Treatment of DED
20th Oct 20227:00 amRNSOKYO to participate at 2022 ThinkEquity Conference
8th Sep 20222:30 pmRNSOKYO interview on Bloomberg: RedChip Money Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.